Gene · 715
NIH grants1,659
NIH grants whose papers are about the gene, through NIH's grant-paper links.
41 to 60 of 1,659
Download this page as JSON| Grant | Title | C1R papers | Newest fiscal year |
|---|---|---|---|
| T32CA009120 | UCLA Tumor Immunology Institutional Training Grant | 2 | 2025 |
| T32HL007525 | Training Program in Hematology | 2 | 2025 |
| U24AG021886 | National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD) | 2 | 2025 |
| U24CA271079 | Proteogenomic Characterization of Tumor Tissues and Preclinical Models with High Precision | 2 | 2025 |
| U54MD007586 | The RCMI Program in Health Disparities Research at Meharry Medical College | 2 | 2025 |
| I01CX001553 | Regulatory T Cell Inhibition of Natural Killer Cells in COPD | 1 | 2025 |
| I01RX001475 | Autonomic Regulation of the Immunological Response to Limb Injury | 1 | 2025 |
| I50RX003002 | Center for the Prevention and Treatment of Visual Loss | 1 | 2025 |
| K01AA029474 | The role of PDK4 in alcohol-associated liver disease | 1 | 2025 |
| K08CA270417 | Elucidating cancer-intrinsic mechanisms of perineural invasion in pancreatic cancer | 1 | 2025 |
| K12CA090354 | Training Program in Nervous System Tumors | 1 | 2025 |
| K12GM093857 | Virginia Commonwealth University IRACDA | 1 | 2025 |
| K12GM133314 | IRACDA at Tufts University | 1 | 2025 |
| K23HL159271 | Epidemiology and Biomarkers in Transplant Associated Thrombotic Microangiopathy (TA-TMA): A Prospective Validation Cohort Study | 1 | 2025 |
| KL2TR002346 | Washington University Institute of Clinical and Translational Sciences (KL2) | 1 | 2025 |
| P01AI108545 | Synergies among inhibitory receptors in tolerance and disease | 1 | 2025 |
| P01AI138949 | Ixodes scapularis Immuno-Developmental and Metabolic Signaling Pathways and Interference with Ticks and Tick-borne Pathogens | 1 | 2025 |
| P01AI162242 | Impact of Antibody Effector Function Diversity on Antiviral Activity In Situ | 1 | 2025 |
| P01CA117969 | Genetics and Biology of Pancreatic Ductal Adenocarcinoma | 1 | 2025 |
| P01CA163205 | Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/715/grants?page=3